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Abstract
The tumor suppressor p53 plays a crucial role in cellular growth control inducing a plethora of different response pathways.
The molecular mechanisms that discriminate between the distinct p53-responses have remained largely elusive. Here, we
have analyzed the p53-regulated pathways induced by Actinomycin D and Etoposide treatment resulting in more growth
arrested versus apoptotic cells respectively. We found that the genome-wide p53 DNA-binding patterns are almost identical
upon both treatments notwithstanding transcriptional differences that we observed in global transcriptome analysis. To
assess the role of post-translational modifications in target gene choice and activation we investigated the genome-wide
level of phosphorylation of Serine 46 of p53 bound to DNA (p53-pS46) and of Serine 15 (p53-pS15). Interestingly, the extent
of S46 phosphorylation of p53 bound to DNA is considerably higher in cells directed towards apoptosis while the degree of
phosphorylation at S15 remains highly similar. Moreover, our data suggest that following different chemotherapeutical
treatments, the amount of chromatin-associated p53 phosphorylated at S46 but not at pS15 is higher on certain apoptosis
related target genes. Our data provide evidence that cell fate decisions are not made primarily on the level of general p53
DNA-binding and that post-translationally modified p53 can have distinct DNA-binding characteristics.
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Introduction
The tumor suppressor p53 plays a central role in response to
cellular stress such as DNA damage. In a wide variety of human
cancers the pathways leading to growth arrest or apoptosis are
disrupted. This highly correlates with p53 mutations, especially in
the DNA-binding domain [1]. In response to a cellular stress signal
p53 gets stabilized and regulates the expression of target genes
involved in growth arrest, apoptosis and other responses [2].
An important question for the p53 research is whether and how
p53 discriminates between target genes to be activated or
repressed, resulting in a particular cellular outcome. Several
models have been proposed to explain how p53 determines the
cellular outcome. Several lines of evidence lead to the threshold
model in which the amount of p53 protein present in a cell
determines if cells go into apoptosis [3]. Other models have been
described in which co-factors, p53-binding factors and post-
translational modifications play an important role in p53 target
gene selection [4]. In the selective binding model, selectivity of
target gene activation and repression takes place at the level of
DNA-binding. In the selective context model, p53 is thought to
first bind to all accessible sites in the genome after which other
determinants like p53-binding factors and the presence of p53
PTMs determine the cellular outcome. Yet, it remains unresolved
which of these models of p53 target gene choice best reflects the
actual in vivo situation upon different stress signals.
The p53 activity is tightly regulated in the cell by co-factors [5]
as well as post-translational modifications [6]. Among the p53-
binding proteins that are described to influence the cellular
outcome are the apoptosis-stimulating proteins of p53 (ASPP)
proteins that interact with p53 and specifically stimulate p53-
induced apoptosis but not cell cycle arrest and iASPP that inhibits
p53-mediated apoptosis [7]. The Hematopoietic Zinc Finger
protein (HZF) that is induced by p53 and binds to its DNA-
binding domain, facilitates p53-binding to cell cycle arrest target
genes resulting in preferential cell cycle arrest [8]. Also the human
cellular apoptosis susceptibility protein (hCAS/CSE1L) has been
shown to influence the p53-mediated transactivation by binding to
a subset of p53 target genes [9].
A series of post-translational modifications of p53 is involved in
mediating transactivation upon stress by stabilizing and activating
p53, such as phosphorylation, acetylation, methylation, neddyla-
tion, sumoylation and ubiquitination [6,10,11]. Besides stabiliza-
tion and activation, several post-translational modifications are
thought to play a role in target gene selectivity [3,4,10]. Numerous
Serine and Threonine residues of p53 are targets for phosphor-
ylation. Some amino acids that are phosphorylated upon stress
lead to a general stabilization and activation of p53, such as Serine
15, which is phosphorylated in an ATM-dependent manner [12].
Phosphorylation of Serine 46, on the other hand, is proposed to be
involved in the selectivity of apoptotic target genes, such as the p53
apoptosis inducing protein 1 (p53AIP1) in response to DNA
damage [13]. This phosphorylation site can be regulated by
several kinases, by e.g. homeodomain interacting protein kinase 2
(HIPK2) [14,15], dual-specificity tyrosine-phosphorylation-regu-
lated kinase 2 (DYRK2) [16], ataxia-telangiectasia mutated (ATM)
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kinase catalytic subunit a (AMPKa) [19] or p38 mitogen-activated
protein kinase (p38 MAPK) [20]. The fact that several kinases can
phosphorylate Serine 46 suggests that this may be a very important
modification for the regulation and function of p53. One of the
most interesting current research questions is the exact contribu-
tion of this phosphorylation site to the selectivity of the global
transcriptional program of p53.
To investigate how the selectivity of p53 target genes is globally
mediated, we have performed genome-wide DNA-binding and
expression analysis upon different chemotherapeutic treatments.
We can show that different treatments induce the transcriptional
activation or repression of treatment specific sets of target genes
while p53 binds indiscriminately to a general pool of p53-binding
sites. Importantly, we found that the extent to which chromatin
associated p53 is phosphorylated at Serine 46 increases signif-
icantly upon apoptosis-inducing Etoposide treatment whereas the
amount of DNA-bound p53 that is phosphorylated at Serine 15
remains similar upon both treatments. Finally, we observed
specific differences of binding of p53 phosphorylated at Serine
46 to several direct transcriptional target genes involved in
apoptosis induction.
Results
DNA-binding of p53 upon chemotherapeutic treatment
In order to gain more insight into the molecular basis of p53-
mediated growth arrest versus apoptosis induction, we studied the
transcriptional pathways activated by p53 upon two different
cellular fates. Therefore, we treated U2OS osteosarcoma cells
expressing wild type p53 with two chemotherapeutic reagents,
Actinomycin D to induce cell cycle arrest and Etoposide to
increase the apoptotic cell population (Figure 1A). Treatment with
Etoposide resulted in PARP cleavage and active Caspase 3
(Figure 1B), indicating that the cells are going into apoptosis,
whereas cells treated with Actinomycin D did not. Upon both
Figure 1. Treatment of U2OS cells with Actinomycin D or Etoposide activates p53. (A) Representative cell cycle profiles of U2OS cells
untreated or treated for 24 or 48 hours with 5 nM Actinomycin D or 10 mM Etoposide. (B) Western blot showing p53, and p21, cleaved PARP and
active Caspase-3 protein levels in whole cell extracts of U2OS cells untreated or treated for 24 hours with 5 nM Actinomycin D or 10 mM Etoposide.
TBP is used as loading control. (C) ChIP recovery of p53-binding to the p21 and BAX promoter in U2OS cells treated for 24 hours with 5 nM
Actinomycin D or 10 mM Etoposide. ChIP was performed with a p53-antibody (p53-DO1) and qPCR analysis was performed with primers for the
respective binding sites. Binding to Myoglobin (myo) was used as a negative control. Error bars represent standard deviation of three individual
experiments.
doi:10.1371/journal.pone.0017574.g001
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To study the transcriptional responses upon the treatments, p53
chromatin-immunoprecipitations (ChIPs) were performed to test
for p53-binding to the promoters of the cell cycle inhibitor p21 and
the pro-apoptotic target gene BAX. Upon both treatments the
cell-cycle arrest as well as the pro-apoptotic target genes were
bound by p53 as shown in specific chromatin-immunoprecipita-
tion experiments (Figure 1C), whereas chromatin-immunoprecip-
itations with IgG instead of a specific antibody did not result in a
specific enrichment of target sites (Figure S1A). Thus, the question
arises how under different cell fate decisions the respective target
gene specificity is regulated. To obtain insight into this question,
we analyzed the global DNA binding sites of p53 under both
conditions using ChIP-sequencing (ChIP-seq). We identified 2,132
p53-binding sites upon Actinomycin D treatment and 2,920 upon
Etoposide treatment (Table 1) using the MACS peak recognition
[21]. Identified p53-binding sites were annotated and the locations
of p53-binding sites were assigned to RefSeq genes [22].
Surprisingly, most DNA-binding sites of p53 were present upon
both treatments (Figure 2A). Using strict peak settings, as many as
76% of the peaks detected in Actinomycin D treated cells are also
bound by p53 upon Etoposide (Table 2). The similarity in binding
occupancy following either treatment is further substantiated when
the number of reads per peak (RPP) for Actinomycin D versus
Etoposide is plotted (Figure 2B), which shows a good correlation of
the RPP between both treatments (R
2=0.70). Furthermore, the
common binding sites are the most prevalent peaks as shown by a
median number of reads per peak (RPP) of 26 and 33 for
Actinomycin D and Etoposide treatment respectively, while the
peaks preferential for Actinomycin D or Etoposide were
significantly lower than the common peaks with a median RPP
of 12 (Actinomycin D, P,0.0001, two-sample Kolmogorov–
Smirnov test) and 16 (Etoposide, P,0.0001) (Figure 2C). Addi-
tionally, the number of reads detected in ‘the respective other
treatment’ is still significantly higher than background (P,0.0001,
Figure S1B), but lower than peak-threshold and therefore not
detected as common peaks. Thus, the low, preferentially detected
binding sites are most likely also occupied by p53 upon the
respective other treatment but fall just under the threshold in that
treatment. Decreasing the threshold for peak detection includes
these peaks, but would at the same time increase the number of
false positives detected. Therefore, we chose to use a strict
threshold to detect and subsequently analyze only high-confidence
p53 peaks. Upon both treatments the identified peaks are
significantly enriched at transcriptional start site (TSS) flanking
regions encompassing promoters as well as the broader promoter-
enhancer regions, 5–25 kb up- or downstream from the respective
genes (Figure 2D). To characterize sequences underlying the
binding sites, we analyzed them with the p53scan algorithm [23]
and found that the vast majority of the identified p53-binding sites
(86% and 88% respectively) contain a p53 consensus motif
irrespective of the treatment. Comparing our binding data upon
Actinomycin D treatment or Etoposide treatment with another
available global p53 binding set, the data set from Wei et al. [24],
we found that 72% and 81% respectively of the PET3+ binding
sites from Wei et al. were bound in our p53 binding set upon
Actinomycin D or Etoposide treatment, indicating a high overlap
irrespective of cell line or treatment used.
Thus, upon two different chemotherapeutic treatments we
found very similar overall genome-wide binding sites of p53. We
hypothesize that the general p53-binding patterns that overlap to a
large extent are unlikely to fully account for the biological
differences observed upon these two treatments in U2OS cells.
Expression analysis upon Actinomycin D and Etoposide
treatment
To study the effect of Actinomycin D or Etoposide treatment on
the transcriptome level, we analyzed respective expression changes
by performing microarray analysis experiments on Affymetrix
Human Exon Arrays (Affymetrix, Santa Clara, CA). Analyzing the
expression changes, we found that treatment of U2OS cells with
either Actinomycin D or Etoposide resulted in treatment-specific
expression patterns as demonstrated in the plot showing ratios of
gene expression changes upon Actinomycin D treatment versus
Etoposide treatment (Figure 3A). The correlation between both
treatments is 0.36, which is significantly lower than the correlation
for p53 binding between the two treatments which is 0.70. Thus,
many genes are preferentially up- or down-regulated upon one of
the two treatments.
To analyze the relationship between target genes that were
bound by p53 and target genes changing expression upon
treatment, we correlated the binding with the expression data
(Affymetrix core transcripts). In total, upon Actinomycin D
treatment 1320 genes have a p53-binding site in close proximity
i.e. within the gene body or 25 kb up- or downstream of a gene, of
which 185 (14%) changed at least 1.7 fold in expression (Table S1)
and upon Etoposide treatment 1,710 genes have a p53-binding site
in close proximity of which 177 (10%) changed at least 1.7 fold
(Table S2). To analyze whether high expression changes also
correlate with stronger binding in the ChIP-seq data we plotted
the RPP for p53 versus the expression change. We observed no
significant correlation between the number of reads in the ChIP-
seq experiments and change in expression in either treatment,
neither for up- nor for down-regulated transcripts (Figure S2). To
further study the relationship between target genes which have a
p53-binding site nearby and expression changes, we clustered
genes that change in their level of expression and have a p53-
binding site using a k-Means algorithm based on uncentered
correlation of the expression change (Figure 3B). We observed
gene clusters that were clearly differentially regulated only upon
one of the two treatments, such as target gene cluster 4 and 5
(Table S3). Interestingly, we found that genes which are
preferentially upregulated upon either Etoposide (cluster 4) or
Actinomycin D treatment (cluster 5) are nonetheless indiscrimi-
nately bound by p53 upon both treatments as shown for the
indicated examples of the SerpinB5 and FGD3 genes for cluster 4
and the CDC42EP3 and PDE4C genes for cluster 5 (Figure 3C).
Comparing the RPP between the two treatments of the cluster 4 or
5 target genes shows that the target genes of these two clusters,
highly correlate with respect to their p53 DNA binding
(Figure 3D), although they show differential expression upon the
two treatments. Thus, our data show that differentially expressed
target genes can be bound by p53 indiscriminately upon both
treatments.
Table 1. Sequenced reads of p53-DO1 ChIP-seq.
Actinomycin D Etoposide
Reads Uniquely mapped reads (millions) 5.4 6.1
Normalized reads (millions) 5.3 5.3
Peaks Number of peaks 2,132 2,920
Average height 35 35
Minimum height 8 8
doi:10.1371/journal.pone.0017574.t001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17574Figure 2. Genome-wide p53-binding profiles. (A) Representative genomic overview of p53-binding to chromosome 19 upon 5 nM Actinomycin
Do r1 0mM Etoposide treatment for 24 h as determined by ChIP-Seq using the Genome analyzer (Illumina) and visualization using the UCSC genome
browser. (B) The number of reads per peak (RPP) of p53-binding upon Actinomycin D is plotted versus the RPP of p53-binding upon Etoposide
treatment. To determine the correlation between the RPPs of both treatments the square of the sample correlation coefficient between both
treatments was calculated (R
2=0.70). (C) The average number of reads per peak (RPP) for the common p53 peaks as well as the treatment
preferential peaks upon Actinomycin D or Etoposide treatment are visualized in a boxplot. (D) Genome-wide distribution of the p53-binding sites
relative to RefSeq genes. Locations of binding sites are divided in Transcriptional Start Site (TSS) flanking region (5 kb upstream of TSS+first exon+first
intron), intragenic region (all introns and exons except first), 5 kb downstream (5 kb downstream of last exon), 5–25 kb up- or downstream of a
RefSeq gene or intergenic regions (everything else). The genomic distribution is defined as the number of nucleotides per region divided by the total
number of nucleotides in the genome. The asterisk represents significant enrichment compared to overall genomic distribution.
doi:10.1371/journal.pone.0017574.g002
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upon chemotherapeutic treatment
Since overall binding patterns do not appear to account for the
selective cellular responses to different treatments, we investigated
whether p53 post-translational modifications could be involved in
the cellular response decision. We set out to investigate the role of
p53 phosphorylated at Serine 46 (S46) in comparison to p53
phosphorylated at Serine 15 (S15), a post-translational modifica-
tion that is thought to activate and stabilize p53 independently of
specific stress signals. Therefore, we analyzed global DNA-binding
of p53 phosphorylated at Serine 46 and 15 by ChIP-sequencing.
We detected p53 phosphorylated at S15 and S46 upon both
treatments in whole cell lysates (Figure 4A). In ChIP-qPCR
experiments we consistently observed a statistically significant
difference in binding of the phosphorylated p53 forms to the BAX
promoter (Figure 4B). In Etoposide treated U2OS cells, about five
times more p53-pS46 is bound to the BAX promoter as compared
to Actinomycin D treated cells. Since BAX is an apoptotic target
gene we assessed whether the higher degree of DNA-binding of
p53 phosphorylated at Serine 46 upon Etoposide treatment is a
general feature of apoptotic target genes. Therefore, we analyzed
the genome-wide DNA binding sites bound by p53 in either
Actinomycin D or Etoposide treatment for binding of p53
phosphorylated at S46 and of p53 phosphorylated at S15 upon
both treatments by performing ChIP-seq (Table 3). Most
strikingly, apoptosis-inducing Etoposide treatment appears to
significantly increase the overall S46 phosphorylation state of
p53 bound to chromatin. The number of genomic locations
occupied by p53 phosphorylated at S46 is ,5.5 times higher upon
Etoposide treatment than upon Actinomycin D treatment
(Figure 4C). For p53 phosphorylation at S15 on the other hand,
we found a similar number of bound regions and most of the
binding sites are bound by p53 phosphorylated at S15 upon both
treatments (Figure 4C and Table 3). Notably, of all p53 DNA
binding sites about 45% (for Actinomycin D treatment) and 37%
(for Etoposide treatment) are bound by phosphorylated p53
(Figure S3). The p53-pS46 subset of binding sites is almost entirely
included in the subset of p53-pS15 upon both treatments
suggesting that all binding sites bound by p53-pS46 are bound
by p53-pS15 as well or the bound proteins are phosphorylated at
both S15 and S46 residues (Figure S3).
To examine whether there is a correlation between p53 binding
strength and phosphorylation status of bound p53, we divided the
general p53-DO1 binding sites into five subgroups, from low (bin
1) to high (bin 5) total number of reads per peak (RPP), and plotted
the fraction of peaks with either modification in each group
(Figure 5A and B). Strikingly, for Etoposide treated cells nearly
70% of the strongest bound sites (bin 5) are bound by p53-pS46,
whereas upon Actinomycin D treatment only 25% of these sites
were bound by p53-pS46 (Figure 5B). For p53-pS15, on the other
hand, we could not detect this difference, this modification was
equally found within the highest bound sites (Fig. 5A). Thus, we
observed that upon Etoposide treatment significantly more of p53
bound to strong binding sites is phosphorylated at S46 than upon
Actinomycin D treatment. For a direct comparison of the post-
translationally modified p53 and its DNA binding upon the two
different treatments, we plotted the RPP for p53-pS15 and p53-
pS46 upon Actinomycin D versus Etoposide treatment (Figure 5C
and D). For p53-pS15, the RPP correlates well between both
treatments (R
2 of 0.82), implying p53 phosphorylated at S15 is
bound to similar sites with comparable strength upon both
treatments (Figure 5C). On the other hand, the correlation for
p53-pS46 between both treatments is considerably lower (R
2 of
0.63) (Figure 5D). Thus, there are numerous target sites that upon
Etoposide treatment are bound by p53 that is phosphorylated at
S46 to a higher extent than upon Actinomycin D treatment.
Among those target genes that are differentially bound by p53
phosphorylated at S46 are also the two known apoptosis related
target genes BAX and PUMA. We found that for these apoptotic
target genes BAX and PUMA binding of p53 phosphorylated at
S46 was more than 2-fold higher upon Etoposide treatment than
upon Actinomycin D treatment (Figure S4). This difference is not
found for the two cell cycle related target genes, p21 and MDM2
upon Actinomycin D and Etoposide treatment (Figure S4). p21
and MDM2 show comparable binding of phosphorylated p53
upon both treatments. Interestingly, the extent of DNA-bound p53
that is phosphorylated at pS15 was similar between all four target
genes (Figure S4).
Functional annotation of target genes bound by p53
phosphorylated at S46
We performed a functional annotation clustering using DAVID
[25] of target genes that were bound by p53 phosphorylated at S46
to analyze their potential biological roles. Upon Etoposide
treatment several functional clusters contain significantly enriched
sets of p53 target genes (corrected P-value (Benjamini),0.01)
(Table 4), whereas upon Actinomycin D treatment, no set of target
genes involved in a specific biological category is significantly
enriched (data not shown). The most enriched cluster upon
Etoposide treatment is the p53-signaling pathway, followed by the
functional categories of nuclear envelope and cell cycle regulation
(Table 4). Interestingly, several genes involved in apoptosis are also
present (cluster 15, Table 4). Among those are well known p53
apoptotic target genes like BAX, PUMA (BBC3), BCL2L1,
TRIAP1 and TNFRSF6 as well as genes which have been
implicated generally with p53-signaling before like STK17A,
ZMAT3, LGALS7 and BIRC8. Thus, p53 phosphorylated at S46
is bound to a broad spectrum of target genes of which the
apoptosis genes constitute a specific subset.
Expression analysis of differentially bound p53-pS46
target genes
We investigated in more detail those p53 binding sites showing
stronger binding of p53 phosphorylated at S46 as well as an
expression change upon Etoposide treatment. We identified 98
binding sites close to 94 unique genes which differ at least 1.2 fold
in expression between Actinomycin D and Etoposide (Table S4).
We validated a random set of these binding sites by ChIP-qPCR
and monitored expression changes of the respective target genes
upon Actinomycin D or Etoposide treatment by RT-qPCR. For
all tested target sites the binding of p53 phosphorylated at S46 is
higher upon Etoposide treatment than upon Actinomycin D
treatment (Figure 6A) while the difference of binding of p53
phosphorylated at S15 is much smaller upon the two treatments
(Figure S5). Testing whether the higher degree of binding of p53
phosphorylated at S46 is correlated with an expression change of
Table 2. Overlap of p53-binding sites.
Binding sites
Actinomycin D 2,132
Etoposide 2,920
Overlap 1,612
doi:10.1371/journal.pone.0017574.t002
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and TGFA a statistically significant difference in expression
change for Etoposide versus Actinomycin D treatment (Figure 6B).
Analyzing the ChIP-sequencing data of those three target genes,
we indeed see that while the binding of p53 phosphorylated at S15
remains almost unchanged upon both treatments, the binding of
p53 phosphorylated at S46 is clearly stronger (2-fold) upon
Etoposide treatment than upon Actinomycin D treatment
(Figure 6C). Thus, the tested target genes show a distinctive
binding pattern of p53 phosphorylated at S46 upon Etoposide
treatment which in some cases is also accompanied by a respective
expression change. Thus, we conclude that it is feasible that post-
translational modifications of p53, in particular the phosphoryla-
tion of S46 can contribute to the p53 target gene selectivity and
can therefore influence differential p53 cellular response pathways.
Discussion
An essential issue in the present p53 research is to understand
the molecular basis for the discrimination between the widely
varying cellular responses upon p53 activation. The regulation
mechanisms of p53’s ability to selectively activate or repress a
certain set of target genes have remained elusive. To explain the
possible regulation mechanisms several models have been
Figure 4. DNA-binding of p53 phosphorylated at Serine 15 and 46. (A) Western blot showing protein levels of p53, p53 phosphorylated at
Serine 15 (p53-pS15) and p53 phosphorylated at Serine 46 (p53-pS46) in whole cell lysates of U2OS cells untreated or treated for 24 hours with 5 nM
Actinomycin D or 10 mM Etoposide. TBP is shown as loading control. (B) ChIP-qPCR recovery of p53-pS15 and p53-pS46 binding to the p21 and BAX
promoter in U2OS cells treated for 24 hours with 5 nM Actinomycin D or 10 mM Etoposide. ChIP was performed with p53-pS15-antibody or p53-
pS46-antibody and qPCR analysis was performed with primers for respective binding sites. Myoglobin (myo) was used as a negative control. Error
bars represent standard deviation of three individual experiments. (C) Overlap of p53-pS46 binding sites (left panel) and p53-pS15 binding sites (right
panel) of ChIP-seq performed after 5 nM Actinomycin D or 10 mM Etoposide treatment for 24 h using the Genome analyzer (Illumina).
doi:10.1371/journal.pone.0017574.g004
Figure 3. Global expression analysis upon Actinomycin D and Etoposide treatment. (A) Global expression analysis of U2OS cells treated for
24 hours with Actinomycin D or Etoposide was performed using Affymetrix exon arrays. The ratio of expression changes (log2 signal intensity
24 hours/0 hours) upon Actinomycin D treatment versus Etoposide treatment was plotted against each other. (B) K-Means clustering results of the
expression change of genes with a p53-binding site within the transcript or 25 kb up- or downstream upon Actinomycin D or Etoposide treatment.
Upregulation is indicated in red; downregulation in green. (C) p53-binding as determined by ChIP-Seq visualized using the UCSC Genome Browser to
two genes which are preferentially upregulated upon Etoposide (cluster 4) and two genes which are preferentially upregulated upon Actinomycin D
treatment (cluster 5). (D) The number of reads per peak (RPP) of p53-binding upon Actinomycin D is plotted versus the RPP of p53-binding upon
Etoposide for the target genes of cluster 4 (left) and cluster 5 (right). To determine the correlation between the RPP of both treatments the square of
the sample correlation coefficient between both treatments was calculated (R
2=0.69 and R
2=0.77 respectively).
doi:10.1371/journal.pone.0017574.g003
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Uniquely mapped
reads (millions)
Normalized reads
(millions)
Number of peaks
overlapping with
DO1 Average height Minimum height
Actinomycin D p53-pS15 8.2 5.3 1,173 20 6
p53-pS46 5.3 5.3 140 16 7
Etoposide p53-pS15 8.7 5.3 1,099 24 6
p53-pS46 6.8 5.3 518 20 6
doi:10.1371/journal.pone.0017574.t003
Figure 5. Analysis of genome-wide binding profiles of phosphorylated p53. (A–B) Percentage of overall p53-binding sites as obtained from
ChIP-seq that are enriched for binding of phosphorylated p53, p53-pS15 or p53-pS46, relative to peak strength. The identified overall p53-binding
sites were ranked according to the number of reads per peak and divided into five groups ranking from low to high. For each bin the percentage of
p53-binding sites containing also a peak for p53-pS15 (A) or p53-pS46 (B) was plotted. (C–D) Number of reads per peak (RPP) of p53-pS15 (C) and
p53-pS46 binding (D) in Actinomycin D versus Etoposide treated cells. To determine the correlation between Actinomycin D versus Etoposide RPP
the square of the sample correlation coefficient between both treatments for p53-pS15 (R
2=0.82) and p53-pS46 (R
2=0.63) was calculated.
doi:10.1371/journal.pone.0017574.g005
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in the absence of cellular stress and becomes activated upon
cellular stress [26]. In the threshold model the amount of p53
determines cellular outcome [27]. Recently, the existing lines of
evidence have been incorporated into the selective binding model,
in which selectivity of target gene activation and repression takes
place directly at the level of DNA-binding, and the selective
context model. In the selective context model p53 first binds to all
accessible sites in the genome and then other determinants like
post-translational modifications of p53, the presence of co-factors
and chromatin architecture determine cellular outcome [4]. Most
of the experimental evidence for the molecular mechanism of the
p53 response has been based so far on a selective set of target
genes. Therefore, we set out to gain more insight in global p53-
binding and target gene activation or repression. We compared
genome-wide p53 DNA-binding upon the two different chemo-
therapeutic treatments Actinomycin D and Etoposide by ChIP-seq
and analyzed subsequent expression changes. To elucidate a
possible involvement of post-translational modifications in the
actual target gene selection, we assessed the role of p53-
phosphorylation at Serine 15 and 46.
The overall genome-wide binding pattern of p53 is very similar
between the two different treatments. A large number of binding
sites are occupied by p53 upon both Actinomycin D and Etoposide
treatment. Overall, only a fraction of all bound p53-target genes
actually change in expression upon the particular induction. This is
in line with other studies, which show that the binding of p53 to the
regulatory regions of a target gene is not necessarily directly
correlated to an expression change of every bound gene
[24,28,29,30,31]. In contrast to the similar occupancy of binding
sites, cell cycle analysis and expression profiles show a marked
difference in cellular outcome. Interestingly, we found that even a
subset of genes which display differential expression upon the
treatments was bound by p53 to a comparable degree upon both
treatments. This makes the selective binding model [4] unlikely
since our obtained overall p53-binding data cannot explain the
difference in transcriptional activation upon the different treat-
ments. Thus, it is unlikely that different cellular outcomes can be
explained only on the basis of selective binding of p53.
As suggested in the selective context model, additional levels of
regulation appear to be necessary to mediate target gene selection,
modulated by e.g. either post-translational modifications of p53,
co-factors, p53-binding factors, p53 responsive microRNAs
(miRNAs), p53 family members or chromatin remodeling factors.
While some post-translational modifications (PTMs) are thought to
be necessary for p53 activity in general such as p53 phosphory-
lation at Serine 15 [32], phosphorylation of Serine 46 has been
proposed to be involved in the activation of certain apoptotic
target genes, such as p53 apoptosis inducing protein 1 (p53AIP1)
in response to DNA damage resulting in apoptosis of the cells
[13,15,16,33,34,35,36]. To find out whether the DNA-binding of
p53 phosphorylated at S46 plays a role in target gene selectivity, in
particular for the selection of apoptotic target genes, we studied
genome-wide DNA-binding profiles of p53 phosphorylated at S46,
and analyzed the binding profiles of p53 phosphorylated at S15 in
comparison. As a matter of fact, we detected a considerably higher
degree of p53 phosphorylated at S46 bound to target genes upon
Etoposide treatment, although binding of p53-pS46 is in principle
also present in cells treated with Actinomycin D. Analyzing the
bound targets in more detail, we found that the DNA-binding of
p53 phosphorylated at S46 is not restricted to apoptotic target
genes. Thus, the degree of DNA-bound p53 that is phosphorylated
at S46 is higher upon Etoposide treatment and on a genome-wide
DNA-binding scale a broad spectrum of individual target genes
involved in different cellular functions can be found, including
apoptotic target genes like BAX and PUMA.
Since it has been shown that p53 phosphorylated at pS46 is
involved in selectivity of certain apoptotic target genes, [13,33,34],
we investigated target genes that are enriched for the extent of p53
phosphorylation at S46 of bound p53 only upon Etoposide
treatment. On a genome-wide scale p53 phosphorylated at S46
DNA-binding does not predict the occurrence or magnitude of
expression change of the respective target genes. However, we did
identify a group of target genes enriched for chromatin bound p53
that is phosphorylated at S46 only upon Etoposide treatment,
which do change in expression accordingly. Importantly, this
group includes several apoptosis related genes, like BCL2L1. This
further extends the results of previous studies showing that p53
Table 4. Functional clustering analysis of p53-pS46 bound RefSeq genes, ranked according to corrected P-value (Benjamini).
Annotation cluster 1
st Term cluster Count PValue Benjamini
1 p53 signaling pathway 8 5.63E-05 1.13E-02
2 nuclear envelope 10 1.47E-04 1.20E-01
3 cell cycle arrest 6 1.64E-03 7.63E-01
4 negative regulation of biological process 28 5.44E-05 2.48E-01
5 regulation of anatomical structure, morphogenesis 4 1.13E-02 9.34E-01
6 cytoskeleton 23 4.91E-03 7.60E-01
7 cellular structure, morphogenesis 13 4.96E-03 9.76E-01
8 response to DNA damage stimulus 13 1.18E-04 2.67E-01
9 WW domain 3 1.69E-02 1.00E+00
10 cell communication 56 1.24E-02 9.28E-01
11 cytoskeleton 23 4.91E-03 7.60E-01
12 fibroblast proliferation 3 9.87E-03 9.26E-01
13 cation binding 52 2.36E-02 9.99E-01
14 release of cytochrome c from mitochondria 3 6.33E-03 9.64E-01
15 apoptosis 9 1.66E-02 9.21E-01
doi:10.1371/journal.pone.0017574.t004
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of p53 at Serine 46 [13,33,34]. Our findings indicate that the
Etoposide treatment which results in an increase of apoptotic cells
leads to an enrichment of p53 phosphorylated at S46. This
phosphorylated form of p53 can be bound to certain target genes
involved in apoptosis induction. Furthermore, based on the global,
genome-wide data this does not seem to be the sole functional role
of p53 phosphorylation at S46. Future research using the resource
of targets discovered in this study should expand the functions for
which the phosphorylation of p53 at Serine 46 plays an important
role.
Thus, the finding that differential binding of p53 phosphory-
lated at S46 to a specific subset of target genes might influence the
p53 target gene choice is most likely one of several regulation
layers that are required to mediate the different cellular stress
response. Other modifications of p53 like acetylation of Lysine 320
could be important for the apoptotic response as well [37].
Possibly, crosstalk of several p53 modifications is necessary to
induce the apoptotic stress response. For example, CBP mediated
acetylation of Lysine 382 requires phosphorylation of Serine 46
[14]. Furthermore, the complexity of post-translational modifica-
tions of p53 needs to be taken into consideration to reveal the
functional significance of the single modifications as well as the
sequential interplay of different modifications [38]. Some of the
sites for post-translational modifications are also suggested to be
redundant for the p53 regulation, which makes e.g. the
interpretation of knock-in studies in mice more complex [39].
Thus, future research will have to focus on the interdependent
network of post-translational modifications of p53.
Besides post-translational modifications, chromatin remodeling
is also involved in the target gene selectivity of p53 target genes.
Recently, the human cellular apoptosis susceptibility protein
(hCAS/CSE1L) was described to be involved in changing the
chromatin landscape of p53 target genes [9]. hCas associates with
some p53-target genes and supposedly down-regulates the
methylation levels of histone H3K27, a chromatin mark which is
associated with repression of transcription and heterochromatin
formation. Many p53-binding proteins have been described to
influence the p53-target gene choice as well. The apoptosis-
stimulating proteins of p53 (ASPP) are p53-binding proteins
interacting with p53 and specifically modulating p53-induced
apoptosis but not cell cycle arrest [7]. Another p53-binding protein
is Pin1, which upon DNA damage induced phosphorylation of
p53, binds to p53 and mediates a conformational change of p53
resulting in enhanced p53 transcriptional activity [40]. Although
the recruitment of p53-binding proteins, co-factors and chromatin
remodelers is necessary for most p53 bound target genes to achieve
gene activation or repression, Braastad et al. showed that for some
p53 target genes, like p21, the chromatin seems to be in a
constitutively open state, in which no extensive chromatin
remodeling by co-factors is required for transcriptional regulation
[41]. Since PTMs and co-factors are both involved in p53 target
gene activation, there is a possibility that there is also cross talk
between PTMs and co-factors. Future research should elucidate
how p53 PTMs influence the interaction with co-factors and what
result this has on p53 target gene selectivity. Possibly, co-factor
interactions are regulated by PTMs of p53 and/or interacting
proteins promote changes in p53 PTMs to achieve promoter
specific transactivation.
Furthermore, regulation of target gene expression is likely also
mediated by miRNAs. At the moment the involvement of these
miRNAs in the decision between cell cycle arrest and apoptosis is
intensively studied [42,43,44,45]. In our study, we analyzed
expression changes of p53 bound target genes using Affymetrix
human exon arrays. Since these arrays do not contain miRNAs,
we were not able to detect additional p53 responsive miRNA
clusters. Thus, in the future the role of additional miRNAs on p53
target gene selectivity has to be elucidated.
In conclusion, our results suggest that in general the differential
responses to Actinomycin D and Etoposide treatment cannot be
explained by the overall similar p53 DNA-binding patterns.
Rather, we show here that upon Etoposide treatment the DNA-
bound p53 is phosphorylated at Serine 46 to a higher extent,
showing that this treatment increases the DNA-bound p53 that is
phosphorylated at this specific residue. Thus, in the here studied
cellular system a selective context model is the most likely model to
explain how p53 directs cellular outcome, since additional factors
like the here shown p53-phosphorylation as well as most likely
other PTMs, co-factors and chromatin remodeling influence the
selectivity of target gene transactivation and therefore the cellular
response pathways.
Materials and Methods
Cell culture and drug treatment
The human osteosarcoma cell line U2OS expressing endoge-
nous wild-type p53, a kind gift of Karen Vousden [46], was
maintained in Dulbecco modified Eagle medium supplemented
with 10% fetal calf serum at 37uC. The U2OS cells were treated
with 5 nM Actinomycin D (Sigma) or 10 mM Etoposide (Sigma)
for 24 hours.
Cell cycle analysis
Cells were treated as described above. The cells were fixed with
96% ethanol and stained with propidium iodide (Sigma). DNA
content was analyzed by flow cytometry (Becton Dickinson
FACScan) and analyzed using CellQuest Pro software.
Immunoblotting
To assess protein levels, proteins from whole-cell extracts were
harvested, lysed and separated by SDS-PAGE and analyzed by
Western blotting with a-p53 (DO1, BD PharMingen), a-p53-pS15
(Cell Signaling), a-p53-pS46 (BD PharMingen), a-p21 (Ab1,
Calbiochem), a-PARP (Cell signaling), a-caspase-3 (Abcam) or
a-TBP (Diagenode).
Figure 6. Target genes differentially bound by p53-pS46. (A) ChIP-qPCR recovery of loci which show a higher degree of bound p53
phosphorylated at S46 upon Etoposide treatment in ChIP-seq. U2OS cells were treated with Actinomycin D or Etoposide for 24 hours, before
chromatin was isolated. ChIP was performed with the p53-pS46-antibody and qPCR analysis was performed with primers for the putative binding
sites. Shown is the recovery of p53-pS46 normalized to the recovery of total p53-DO1 binding in Etoposide or Actinomycin D treated U2OS cells. Error
bars represent standard deviation of three individual experiments. (B) Expression change of the respective target genes in U2OS cells treated with
Actinomycin D or Etoposide for 24 hours. After cDNA synthesis qPCR was performed and results were normalized against GAPDH expression. Shown
is fold over untreated cells. Error bars represent standard deviation of three individual experiments. Asterisks indicate statistical significance shown by
Student’s t-test (*=P,0.01). (C) p53-pS15 and p53-pS46 DNA-binding as determined by ChIP-Seq with the Genome analyzer (Illumina) and visualized
using the UCSC genome browser. Shown are binding loci of BCL2L1, FAM46A and TGFA of Actinomycin D treated cells (left panel) and Etoposide
treated cells (right panel).
doi:10.1371/journal.pone.0017574.g006
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Chromatin immunoprecipitation (ChIP) was essentially per-
formed as described by Denissov et al. [47]. The cells were
sonicated using a Bioruptor sonicator (Diagenode) for 15 minutes
at high power, 30 seconds ON, 30 seconds OFF. Antibody
incubation with chromatin from U2OS treated with Actinomycin
D or Etoposide was performed overnight at 4uC with 1–2 mg
antibody DO1 (BD PharMingen), p53-pS15 (Cell Signaling), p53-
pS46 (BD PharMingen) or normal mouse IgG (Santa Cruz
Biotechnology). Real-time PCR was performed using the SYBR
Green mix (Biorad) with the MyIQ machine (Biorad). Primers
used for real-time PCR are available upon request.
Illumina high throughput sequencing
Sequencing samples were prepared according to the manufac-
turers protocol (Illumina). Shortly, adapted sequences were linked
to the generated ChIP, the library was size selected (200–250 bp)
and amplified by PCR. Cluster generation and 36-cycle
sequencing were performed using an Illumina Cluster station
and Genome Analyzer according to the manufacturer’s instruc-
tions. Images acquired from the Genome Analyzer were processed
through the bundled image extraction pipeline (Illumina). All 32-
bp sequence reads were uniquely mapped to the human genome
NCBI build 36.1 (hg18) with zero or one mismatch allowed using
ELAND software (Illumina). The reads were directionally
extended to 133 bp, corresponding to the length of the original
fragments used for sequencing. For each position in the genome
the number of overlapping sequence reads was determined,
averaged over a 10 bp window and visualized in the UCSC
genome browser (http://genome.ucsc.edu).
ChIP-seq data analysis
The mapped reads were normalized between samples by
uniformly removing reads to obtain an identical number of
mapped reads for each experiment. Peak recognition was
performed using Model-based analysis of ChIP-Seq (MACS)
[21] with a p-value threshold of 1e-7. Artifacts, like spurious peaks
in centromeric and telomeric regions, were removed from the list.
For p53-pS15 and p53-pS46 the binding sites bound by p53 in
either Actinomycin D or Etoposide treatment were analyzed.
Peaks were mapped to RefSeq genes [22], downloaded from the
UCSC Genome Browser, to determine genomic location. The
location and score of the p53 motif within the 200 bp peaks was
determined using p53scan with default settings (www.ncmls.nl/
bioinfo/p53scan/) [23].
RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini kit according
to protocol (Qiagen). For cDNA synthesis, reverse transcription
was performed with 1 mg of the total RNA, oligodT anchor
primers, dNTPS, DTT, buffer and Superscript Retrotranscriptase
(Invitrogen). cDNA was analyzed by qPCR using a MyIQ
machine (Biorad). Primers used for real-time PCR are available
upon request.
Microarray hybridization and expression analysis
RNA from U2OS cells untreated or treated 24 hours with
Actinomycin D or Etoposide was extracted using the RNeasy Mini
kit according to protocol (Qiagen). A DNase I (Qiagen) digestion
step was included to eliminate DNA contamination. Quantity and
quality was determined by Nanodrop ND1000 and Agilent
Bioanalyzer 2100. Two microgram of total RNA was used for
hybridizations on the Gene Chip Human Exon 1.0 ST Array
(Affymetrix) according to the manufacturer’s protocol (Gene
ChipH Whole Transcript (WT) Sense Target Labeling Assay
Manual). Subsequently the cell-files were imported into PartekH
(PartekH Genomic Suite software, version 6.4 Copyright  2008
Partek Inc., St. Louis, MO, USA) where only core exons were
extracted and normalized using the Robust Multiarray Analysis
(RMA) [48] algorithm with GC background correction. Core
transcript summaries were calculated using the mean intensities of
the corresponding probe sets [49]. All samples were performed in
duplicates. An average expression value for each time point (0 and
24 hours) was obtained by averaging the median normalized gene-
level expression value for the two replicate per time point. The
expression values for 24 hours were divided by the expression
values of 0 hours resulting in a ratio for each gene. Affymetrix core
transcripts with a p53-binding site within the transcript or 25 kb
up- or downstream were clustered into 10 groups with Cluster3
[50] using the k-Means algorithm based on uncentered correla-
tion. Results were visualized with Java TreeView [51].
Data availability
The data have been deposited in NCBI’s Gene Expression
Omnibus [52] and are accessible through GEO Series accession
number GSE22186 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE22186).
Supporting Information
Figure S1 Characterization of preferential peaks. (A)
ChIP recovery of p53-binding to the p21 and BAX promoter
compared to IgG as a negative control in U2OS cells treated for
24 hours with 5 nM Actinomycin D (left panel) or 10 mM
Etoposide (right panel). ChIP was performed with a p53-antibody
(p53-DO1) or an IgG antibody and qPCR analysis was performed
with primers for the respective binding sites. Binding to Myoglobin
(myo) was used as a negative control. Error bars represent
standard deviation of three individual experiments. (B) The
average number of reads per peak for the preferential p53 peaks
as well as random reads upon Actinomycin D treatment (left panel)
or Etoposide treatment (right panel) are visualized in a boxplot.
(TIF)
Figure S2 Correlation between p53-binding and expres-
sion change. Change in expression ratio was plotted against the
p53 number of reads per peak (RPP) of the ChIP-Seq experiment
for Actinomycin D (left panel) and Etoposide (right panel)
treatment.
(TIF)
Figure S3 Binding overlap between different experi-
ments. Overlap op p53, p53-pS15 and p53-pS46 binding as
determined by ChIP-Seq in U2OS cells treated with Actinomycin
D (left panel) or Etoposide (right panel) for 24 hours.
(TIF)
Figure S4 Binding of phosphorylated p53 to apoptotic
and growth arrest target genes. p53, p53-pS15 and p53-
pS46 binding as determined by ChIP-Seq with the Genome
analyzer (Illumina) and visualized using the UCSC genome
browser. Shown are binding loci of the apoptotic target genes
BAX and PUMA, and binding loci of two growth arrest target
genes p21 and MDM2 of Actinomycin D treated cells (left panel)
and Etoposide treated cells (right panel).
(TIF)
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pS46 target genes. ChIP-qPCR recovery of p53-pS15 at loci
which show a higher degree of p53 phosphorylated at S46 upon
Etoposide treatment. U2OS cells were treated with Actinomycin
D or Etoposide for 24 hours, before chromatin was isolated. ChIP
was performed with p53-pS15-antibody and qPCR analysis was
performed with primers for the putative binding sites. Shown is the
recovery of p53-pS15 normalized to the recovery of total p53-
DO1 binding in Etoposide or Actinomycin D treated U2OS-cells.
Error bars represent standard deviation of three individual
experiments.
(TIF)
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